Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

Autor: Giacomo Caldarola, A Chiricozzi, M Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, M Mariani, G Fabbrocini, P Quaglino, L Bianchi, A Parodi, K Peris, C De Simone
Přispěvatelé: Caldarola, G, Chiricozzi, A, Megna, M, Dapavo, P, Giunta, A, Burlando, M, Malagoli, P, Dini, V, Mariani, M, Fabbrocini, G, Quaglino, P, Bianchi, L, Parodi, A, Peris, K, De Simone, C
Rok vydání: 2023
Předmět:
Zdroj: Expert Opinion on Biological Therapy. 23:365-370
ISSN: 1744-7682
1471-2598
DOI: 10.1080/14712598.2023.2193288
Popis: Background: Confirmatory data on long-term effectiveness and safety of ixekizumb in psoriatic patients from real-world studies are needed. Objectives: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real-world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab. Methods: A retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed, descriptively analyzed using Kaplan-Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered of clinical importance. Results: A total of 306 patients was enrolled. The overall drug survival at 12, 24 and 36 months of treatment with ixekizumab was 92.11%, 83.85% and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017). Conclusions: We found that ixekizumab is a biological agent characterized by a long term effectiveness, not influenced by several clinical factors and associated with a good safety profile.
Databáze: OpenAIRE
Externí odkaz: